TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global and United States RNA-Based Therapeutics and Vaccines Market Report & Forecast 2022-2028

Global and United States RNA-Based Therapeutics and Vaccines Market Report & Forecast 2022-2028

  • Category:Life Sciences
  • Published on : 30 September 2022
  • Pages :102
  • Formats:
  • Report Code:SMR-7399794
OfferClick for best price

Best Price: $3480

RNABased Therapeutics Vaccines Market Size, Share 2022


Market Analysis and Insights: Global RNABased Therapeutics Vaccines Market

The global RNABased Therapeutics Vaccines market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global RNABased Therapeutics Vaccines market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global RNABased Therapeutics Vaccines market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global RNABased Therapeutics Vaccines market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global RNABased Therapeutics Vaccines market.

Global RNABased Therapeutics Vaccines Scope and Market Size

RNA-Based Therapeutics and Vaccines market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global RNA-Based Therapeutics and Vaccines market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the RNA-Based Therapeutics and Vaccines market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type

RNA-Based Therapeutics

RNA-Based Vaccines

Segment by Application

Oncology

Immunology

Ophthalmology

Cardiovascular Diseases

Infectious Diseases

Genetic Diseases

Others

By Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

U.A.E

By Company

Alnylam Pharmaceuticals

Arbutus Biopharma

Arrowhead Pharmaceuticals

BioNTech

CureVac

Dicerna Pharmaceuticals

Regulus Therapeutics

Marina Biotech

MiRagen Therapeutics

Moderna Therapeutics

Quark Pharmaceuticals

Roche

Sylentis

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes RNABased Therapeutics Vaccines product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of RNABased Therapeutics Vaccines, with price, sales, revenue, and global market share of RNABased Therapeutics Vaccines from 2019 to 2022.

Chapter 3, the RNABased Therapeutics Vaccines competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the RNABased Therapeutics Vaccines breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the RNABased Therapeutics Vaccines market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of RNABased Therapeutics Vaccines.

Chapter 13, 14, and 15, to describe RNABased Therapeutics Vaccines sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 RNABased Therapeutics Vaccines Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes Report Details
Report Title Global and United States RNA-Based Therapeutics and Vaccines Market Report & Forecast 2022-2028
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2021
Forecast Year 2029
Number of Pages 102 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Study Coverage
1.1 RNA-Based Therapeutics and Vaccines Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million) Introduction
1.2 Global RNA-Based Therapeutics and Vaccines Outlook 2017 VS 2022 VS 2028
1.2.1 Global RNA-Based Therapeutics and Vaccines Market Size for the Year 2017-2028
1.2.2 Global RNA-Based Therapeutics and Vaccines Market Size for the Year 2017-2028
1.3 RNA-Based Therapeutics and Vaccines Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States RNA-Based Therapeutics and Vaccines in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of RNA-Based Therapeutics and Vaccines Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 RNA-Based Therapeutics and Vaccines Market Dynamics
1.4.1 RNA-Based Therapeutics and Vaccines Industry Trends
1.4.2 RNA-Based Therapeutics and Vaccines Market Drivers
1.4.3 RNA-Based Therapeutics and Vaccines Market Challenges
1.4.4 RNA-Based Therapeutics and Vaccines Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 RNA-Based Therapeutics and Vaccines by Type
2.1 RNA-Based Therapeutics and Vaccines Market Segment by Type
2.1.1 RNA-Based Therapeutics
2.1.2 RNA-Based Vaccines
2.2 Global RNA-Based Therapeutics and Vaccines Market Size by Type (2017, 2022 & 2028)
2.3 Global RNA-Based Therapeutics and Vaccines Market Size by Type (2017-2028)
2.4 United States RNA-Based Therapeutics and Vaccines Market Size by Type (2017, 2022 & 2028)
2.5 United States RNA-Based Therapeutics and Vaccines Market Size by Type (2017-2028)
3 RNA-Based Therapeutics and Vaccines by Application
3.1 RNA-Based Therapeutics and Vaccines Market Segment by Application
3.1.1 Oncology
3.1.2 Immunology
3.1.3 Ophthalmology
3.1.4 Cardiovascular Diseases
3.1.5 Infectious Diseases
3.1.6 Genetic Diseases
3.1.7 Others
3.2 Global RNA-Based Therapeutics and Vaccines Market Size by Application (2017, 2022 & 2028)
3.3 Global RNA-Based Therapeutics and Vaccines Market Size by Application (2017-2028)
3.4 United States RNA-Based Therapeutics and Vaccines Market Size by Application (2017, 2022 & 2028)
3.5 United States RNA-Based Therapeutics and Vaccines Market Size by Application (2017-2028)
4 Global RNA-Based Therapeutics and Vaccines Competitor Landscape by Company
4.1 Global RNA-Based Therapeutics and Vaccines Market Size by Company
4.1.1 Top Global RNA-Based Therapeutics and Vaccines Companies Ranked by Revenue (2021)
4.1.2 Global RNA-Based Therapeutics and Vaccines Revenue by Player (2017-2022)
4.2 Global RNA-Based Therapeutics and Vaccines Concentration Ratio (CR)
4.2.1 RNA-Based Therapeutics and Vaccines Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of RNA-Based Therapeutics and Vaccines in 2021
4.2.3 Global RNA-Based Therapeutics and Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global RNA-Based Therapeutics and Vaccines Headquarters, Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million) Type
4.3.1 Global RNA-Based Therapeutics and Vaccines Headquarters and Area Served
4.3.2 Global RNA-Based Therapeutics and Vaccines Companies Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into RNA-Based Therapeutics and Vaccines Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States RNA-Based Therapeutics and Vaccines Market Size by Company
4.5.1 Top RNA-Based Therapeutics and Vaccines Players in United States, Ranked by Revenue (2021)
4.5.2 United States RNA-Based Therapeutics and Vaccines Revenue by Players (2020, 2021 & 2022)
5 Global RNA-Based Therapeutics and Vaccines Market Size by Region
5.1 Global RNA-Based Therapeutics and Vaccines Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global RNA-Based Therapeutics and Vaccines Market Size by Region (2017-2028)
5.2.1 Global RNA-Based Therapeutics and Vaccines Market Size by Region: 2017-2022
5.2.2 Global RNA-Based Therapeutics and Vaccines Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America RNA-Based Therapeutics and Vaccines Market Size YoY Growth 2017-2028
6.1.2 North America RNA-Based Therapeutics and Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe RNA-Based Therapeutics and Vaccines Market Size YoY Growth 2017-2028
6.3.2 Europe RNA-Based Therapeutics and Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America RNA-Based Therapeutics and Vaccines Market Size YoY Growth 2017-2028
6.4.2 Latin America RNA-Based Therapeutics and Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa RNA-Based Therapeutics and Vaccines Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa RNA-Based Therapeutics and Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Alnylam Pharmaceuticals
7.1.1 Alnylam Pharmaceuticals Company Details
7.1.2 Alnylam Pharmaceuticals Business Overview
7.1.3 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
7.1.4 Alnylam Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.1.5 Alnylam Pharmaceuticals Recent Development
7.2 Arbutus Biopharma
7.2.1 Arbutus Biopharma Company Details
7.2.2 Arbutus Biopharma Business Overview
7.2.3 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Introduction
7.2.4 Arbutus Biopharma Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.2.5 Arbutus Biopharma Recent Development
7.3 Arrowhead Pharmaceuticals
7.3.1 Arrowhead Pharmaceuticals Company Details
7.3.2 Arrowhead Pharmaceuticals Business Overview
7.3.3 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
7.3.4 Arrowhead Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.3.5 Arrowhead Pharmaceuticals Recent Development
7.4 BioNTech
7.4.1 BioNTech Company Details
7.4.2 BioNTech Business Overview
7.4.3 BioNTech RNA-Based Therapeutics and Vaccines Introduction
7.4.4 BioNTech Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.4.5 BioNTech Recent Development
7.5 CureVac
7.5.1 CureVac Company Details
7.5.2 CureVac Business Overview
7.5.3 CureVac RNA-Based Therapeutics and Vaccines Introduction
7.5.4 CureVac Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.5.5 CureVac Recent Development
7.6 Dicerna Pharmaceuticals
7.6.1 Dicerna Pharmaceuticals Company Details
7.6.2 Dicerna Pharmaceuticals Business Overview
7.6.3 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
7.6.4 Dicerna Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.6.5 Dicerna Pharmaceuticals Recent Development
7.7 Regulus Therapeutics
7.7.1 Regulus Therapeutics Company Details
7.7.2 Regulus Therapeutics Business Overview
7.7.3 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Introduction
7.7.4 Regulus Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.7.5 Regulus Therapeutics Recent Development
7.8 Marina Biotech
7.8.1 Marina Biotech Company Details
7.8.2 Marina Biotech Business Overview
7.8.3 Marina Biotech RNA-Based Therapeutics and Vaccines Introduction
7.8.4 Marina Biotech Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.8.5 Marina Biotech Recent Development
7.9 MiRagen Therapeutics
7.9.1 MiRagen Therapeutics Company Details
7.9.2 MiRagen Therapeutics Business Overview
7.9.3 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Introduction
7.9.4 MiRagen Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.9.5 MiRagen Therapeutics Recent Development
7.10 Moderna Therapeutics
7.10.1 Moderna Therapeutics Company Details
7.10.2 Moderna Therapeutics Business Overview
7.10.3 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Introduction
7.10.4 Moderna Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.10.5 Moderna Therapeutics Recent Development
7.11 Quark Pharmaceuticals
7.11.1 Quark Pharmaceuticals Company Details
7.11.2 Quark Pharmaceuticals Business Overview
7.11.3 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
7.11.4 Quark Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.11.5 Quark Pharmaceuticals Recent Development
7.12 Roche
7.12.1 Roche Company Details
7.12.2 Roche Business Overview
7.12.3 Roche RNA-Based Therapeutics and Vaccines Introduction
7.12.4 Roche Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.12.5 Roche Recent Development
7.13 Sylentis
7.13.1 Sylentis Company Details
7.13.2 Sylentis Business Overview
7.13.3 Sylentis RNA-Based Therapeutics and Vaccines Introduction
7.13.4 Sylentis Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022)
7.13.5 Sylentis Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. RNA-Based Therapeutics and Vaccines Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
Table 2. RNA-Based Therapeutics and Vaccines Market Trends
Table 3. RNA-Based Therapeutics and Vaccines Market Drivers
Table 4. RNA-Based Therapeutics and Vaccines Market Challenges
Table 5. RNA-Based Therapeutics and Vaccines Market Restraints
Table 6. Global RNA-Based Therapeutics and Vaccines Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States RNA-Based Therapeutics and Vaccines Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global RNA-Based Therapeutics and Vaccines Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States RNA-Based Therapeutics and Vaccines Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top RNA-Based Therapeutics and Vaccines Companies in Global Market, Ranking by Revenue (2021)
Table 11. Global RNA-Based Therapeutics and Vaccines Revenue by Player, (US$ Million), 2017-2022
Table 12. Global RNA-Based Therapeutics and Vaccines Revenue Share by Player, 2017-2022
Table 13. Global RNA-Based Therapeutics and Vaccines Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global RNA-Based Therapeutics and Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA-Based Therapeutics and Vaccines as of 2021)
Table 15. Top Players of RNA-Based Therapeutics and Vaccines in Global Market, Headquarters and Area Served
Table 16. Companies Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million) Type
Table 17. Date of International Companies Enter into RNA-Based Therapeutics and Vaccines Market
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Top RNA-Based Therapeutics and Vaccines Players in United States Market, Ranking by Revenue (2021)
Table 20. United States RNA-Based Therapeutics and Vaccines Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 21. United States RNA-Based Therapeutics and Vaccines Revenue Share by Players, 2020, 2021 & 2022
Table 22. Global RNA-Based Therapeutics and Vaccines Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 23. Global RNA-Based Therapeutics and Vaccines Market Size by Region (2017-2022) & (US$ Million)
Table 24. Global RNA-Based Therapeutics and Vaccines Market Size Forecast by Region (2023-2028) & (US$ Million)
Table 25. North America RNA-Based Therapeutics and Vaccines Sales in Value by Country (2017-2028) & (US$ Million)
Table 26. Asia Pacific RNA-Based Therapeutics and Vaccines Sales in Value by Region (2017-2028) & (US$ Million)
Table 27. Europe RNA-Based Therapeutics and Vaccines Sales in Value by Country (2017-2028) & (US$ Million)
Table 28. Latin Americaa RNA-Based Therapeutics and Vaccines Sales in Value by Country (2017-2028) & (US$ Million)
Table 29. Middle East and Africa RNA-Based Therapeutics and Vaccines Sales in Value by Country (2017-2028) & (US$ Million)
Table 30. Alnylam Pharmaceuticals Company Details
Table 31. Alnylam Pharmaceuticals Business Overview
Table 32. Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Product
Table 33. Alnylam Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million)
Table 34. Alnylam Pharmaceuticals Recent Development
Table 35. Arbutus Biopharma Company Details
Table 36. Arbutus Biopharma Business Overview
Table 37. Arbutus Biopharma RNA-Based Therapeutics and Vaccines Product
Table 38. Arbutus Biopharma Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million)
Table 39. Arbutus Biopharma Recent Development
Table 40. Arrowhead Pharmaceuticals Company Details
Table 41. Arrowhead Pharmaceuticals Business Overview
Table 42. Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Product
Table 43. Arrowhead Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million)
Table 44. Arrowhead Pharmaceuticals Recent Development
Table 45. BioNTech Company Details
Table 46. BioNTech Business Overview
Table 47. BioNTech RNA-Based Therapeutics and Vaccines Product
Table 48. BioNTech Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million)
Table 49. BioNTech Recent Development
Table 50. CureVac Company Details
Table 51. CureVac Business Overview
Table 52. CureVac RNA-Based Therapeutics and Vaccines Product
Table 53. CureVac Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million)
Table 54. CureVac Recent Development
Table 55. Dicerna Pharmaceuticals Company Details
Table 56. Dicerna Pharmaceuticals Business Overview
Table 57. Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Product
Table 58. Dicerna Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million)
Table 59. Dicerna Pharmaceuticals Recent Development
Table 60. Regulus Therapeutics Company Details
Table 61. Regulus Therapeutics Business Overview
Table 62. Regulus Therapeutics RNA-Based Therapeutics and Vaccines Product
Table 63. Regulus Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million)
Table 64. Regulus Therapeutics Recent Development
Table 65. Marina Biotech Company Details
Table 66. Marina Biotech Business Overview
Table 67. Marina Biotech RNA-Based Therapeutics and Vaccines Product
Table 68. Marina Biotech Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million)
Table 69. Marina Biotech Recent Development
Table 70. MiRagen Therapeutics Company Details
Table 71. MiRagen Therapeutics Business Overview
Table 72. MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Product
Table 73. MiRagen Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million)
Table 74. MiRagen Therapeutics Recent Development
Table 75. Moderna Therapeutics Company Details
Table 76. Moderna Therapeutics Business Overview
Table 77. Moderna Therapeutics RNA-Based Therapeutics and Vaccines Product
Table 78. Moderna Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million)
Table 79. Moderna Therapeutics Recent Development
Table 80. Quark Pharmaceuticals Company Details
Table 81. Quark Pharmaceuticals Business Overview
Table 82. Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Product
Table 83. Quark Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million)
Table 84. Quark Pharmaceuticals Recent Development
Table 85. Roche Company Details
Table 86. Roche Business Overview
Table 87. Roche RNA-Based Therapeutics and Vaccines Product
Table 88. Roche Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million)
Table 89. Roche Recent Development
Table 90. Sylentis Company Details
Table 91. Sylentis Business Overview
Table 92. Sylentis RNA-Based Therapeutics and Vaccines Product
Table 93. Sylentis Revenue in RNA-Based Therapeutics and Vaccines Business (2017-2022) & (US$ Million)
Table 94. Sylentis Recent Development
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources
List of Figures
Figure 1. RNA-Based Therapeutics and Vaccines Product Picture
Figure 2. Global RNA-Based Therapeutics and Vaccines Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global RNA-Based Therapeutics and Vaccines Market Size 2017-2028 (US$ Million)
Figure 4. United States RNA-Based Therapeutics and Vaccines Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 5. United States RNA-Based Therapeutics and Vaccines Market Size 2017-2028 (US$ Million)
Figure 6. United States RNA-Based Therapeutics and Vaccines Market Share in Global 2017-2028
Figure 7. RNA-Based Therapeutics and Vaccines Report Years Considered
Figure 8. Product Picture of RNA-Based Therapeutics
Figure 9. Product Picture of RNA-Based Vaccines
Figure 10. Global RNA-Based Therapeutics and Vaccines Market Share by Type in 2022 & 2028
Figure 11. Global RNA-Based Therapeutics and Vaccines Market Size by Type (2017-2028) & (US$ Million)
Figure 12. Global RNA-Based Therapeutics and Vaccines Market Share by Type (2017-2028)
Figure 13. United States RNA-Based Therapeutics and Vaccines Market Share by Type in 2022 & 2028
Figure 14. United States RNA-Based Therapeutics and Vaccines Market Size by Type (2017-2028) & (US$ Million)
Figure 15. United States RNA-Based Therapeutics and Vaccines Market Share by Type (2017-2028)
Figure 16. Product Picture of Oncology
Figure 17. Product Picture of Immunology
Figure 18. Product Picture of Ophthalmology
Figure 19. Product Picture of Cardiovascular Diseases
Figure 20. Product Picture of Infectious Diseases
Figure 21. Product Picture of Genetic Diseases
Figure 22. Product Picture of Others
Figure 23. Global RNA-Based Therapeutics and Vaccines Market Share by Application in 2022 & 2028
Figure 24. Global RNA-Based Therapeutics and Vaccines Market Size by Application (2017-2028) & (US$ Million)
Figure 25. Global RNA-Based Therapeutics and Vaccines Market Share by Application (2017-2028)
Figure 26. United States RNA-Based Therapeutics and Vaccines Market Share by Application in 2022 & 2028
Figure 27. United States RNA-Based Therapeutics and Vaccines Market Size by Application (2017-2028) & (US$ Million)
Figure 28. United States RNA-Based Therapeutics and Vaccines Market Share by Application (2017-2028)
Figure 29. North America RNA-Based Therapeutics and Vaccines Market Size Growth Rate 2017-2028 (US$ Million)
Figure 30. U.S. RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 31. Canada RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 32. Europe RNA-Based Therapeutics and Vaccines Market Size Growth Rate 2017-2028 (US$ Million)
Figure 33. Germany RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 34. France RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 35. U.K. RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 36. Italy RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 37. Russia RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 38. Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size Growth Rate 2017-2028 (US$ Million)
Figure 39. China RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 40. Japan RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 41. South Korea RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 42. India RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 43. Australia RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 44. Taiwan RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 45. Indonesia RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 46. Thailand RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 47. Malaysia RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 48. Philippines RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 49. Latin America RNA-Based Therapeutics and Vaccines Market Size Growth Rate 2017-2028 (US$ Million)
Figure 50. Mexico RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 51. Brazil RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 52. Argentina RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 53. Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size Growth Rate 2017-2028 (US$ Million)
Figure 54. Turkey RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 55. Saudi Arabia RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 56. U.A.E RNA-Based Therapeutics and Vaccines Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 57. Alnylam Pharmaceuticals Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2017-2022)
Figure 58. Arbutus Biopharma Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2017-2022)
Figure 59. Arrowhead Pharmaceuticals Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2017-2022)
Figure 60. BioNTech Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2017-2022)
Figure 61. CureVac Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2017-2022)
Figure 62. Dicerna Pharmaceuticals Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2017-2022)
Figure 63. Regulus Therapeutics Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2017-2022)
Figure 64. Marina Biotech Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2017-2022)
Figure 65. MiRagen Therapeutics Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2017-2022)
Figure 66. Moderna Therapeutics Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2017-2022)
Figure 67. Quark Pharmaceuticals Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2017-2022)
Figure 68. Roche Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2017-2022)
Figure 69. Sylentis Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2017-2022)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount